Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice

J N Cohn1

  • 1Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, USA.

Journal of Cardiovascular Pharmacology
|January 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Journal of human hypertension·2012
Same author

Rationale for angiotensin II receptor blocker therapy in chronic heart failure.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2007
Same author

Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.

Journal of human hypertension·2005
Same author

Angiotensin receptor blockers and clinical trials in heart failure.

European heart journal·2003
Same author

Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD).

Vascular medicine (London, England)·2002
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.

Congestive heart failure (Greenwich, Conn.)·2002
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Identifying reliable surrogate markers is crucial for improving cardiovascular clinical trials. Structural changes in the left ventricle and endothelial dysfunction are promising candidates for tracking disease progression and therapeutic efficacy.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Clinical Trials

Background:

  • Current cardiovascular clinical trials focus on reducing morbidity and mortality.
  • Therapeutic efficacy assessment currently lacks efficient guides.
  • Surrogate markers are needed to track disease progression towards clinical endpoints.

Purpose of the Study:

  • To identify and validate potential surrogate markers for cardiovascular disease.
  • To evaluate structural alterations of the left ventricle as surrogate markers.
  • To assess endothelial function abnormalities as potential surrogate markers.

Main Methods:

  • Reviewing existing literature on cardiovascular surrogate markers.
  • Analyzing structural changes in the left ventricle.

Related Experiment Videos

  • Investigating endothelial function and vascular alterations.
  • Discussing methods for quantitating these alterations.

    • Main Results:

    • Structural alterations of the left ventricle are strong candidates for surrogate markers.
    • Endothelial function abnormalities leading to vascular changes are also promising.
    • Validated methods are essential for demonstrating marker sensitivity and specificity.

    Conclusions:

    • Left ventricular structural changes and endothelial dysfunction show potential as cardiovascular surrogate markers.
    • Further validation of quantification methods is required.
    • These markers could enhance the efficiency and effectiveness of cardiovascular clinical trials.